Bicara Therapeutics Inc
Research Bicara Therapeutics Inc (BCAX) on Bullrun: market cap USD 1.62B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBCAX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.62B
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 56.21M
- Free cash flow-USD 116.58M
Valuation Snapshot
latest market cap is USD 1.62B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 137.95M | -USD 107.11M | n/a | -2.52 | USD 96.69M | USD 1.71M | USD 401.45M |
| FY2024 | USD 0 | -USD 68.00M | -USD 74.82M | n/a | -4.05 | USD 489.71M | USD 738.00K | USD 491.88M |
| FY2023 | n/a | -USD 51.99M | -USD 46.21M | n/a | -89.61 | USD 230.44M | USD 657.00K | -USD 148.77M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.62B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 952.59M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 948.34M | n/a | n/a | n/a |
About Bicara Therapeutics Inc
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Bicara Therapeutics Inc's market cap?
Bicara Therapeutics Inc's market capitalization is USD 1.62B.
What does Bicara Therapeutics Inc do?
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.